MicroPort CardioFlow-B (02160) announced that, effective December 15, 2025, Mr. Zhao Liang and Ms. Yan Luying have resigned as executive directors to dedicate more time to the group's management affairs. Additionally, Mr. Zhang Junjie has stepped down as a non-executive director due to personal work arrangements.

Dr. Brian Chang has been appointed as a non-executive director and co-chairman of the board, while Mr. Philippe Wanstok has been named an executive director and vice president of the company. Mr. Deng Aoyi has also been appointed as a non-executive director, effective December 15, 2025.

Furthermore, to better reflect the controlling relationship between the company and its major shareholder, MicroPort Scientific Corporation, and to align with the commercial names "MicroPort CardioFlow" and "微创心通" consistently used in sales, marketing, and daily operations, the company's stock trading abbreviations on the Hong Kong Stock Exchange will change. The English abbreviation will be updated from "CARDIOFLOW-B" to "MP CARDIOFLOW-B," and the Chinese abbreviation will shift from "心通医疗-B" to "微创心通-B," effective at 9:00 a.m. on December 22, 2025.

The company's official English and Chinese names remain "MicroPort CardioFlow Medtech Corporation" and "微创心通医疗科技有限公司," respectively, and its stock code on the Hong Kong Stock Exchange will continue to be "2160."